Background Pemphigus, which is one of vesiculobullous diseases that affect the oral mucosa and skin, is caused by antibody-mediated autoimmune reaction to desmogleins desmosomal transmembrane glycoproteins and leads to acantholysis.

Objective Because early diagnosis and effective treatment minimize the morbidity of pemphigus vulgaris (PV), this review highlights the recent advances and management of oral lesions of PV disease.
Results Recent therapeutic modalities include combining anti-CD20 with corticosteroids. Adjunctive therapies that have proven effective in reducing the indicated dosage of corticosteroids include rituximab intravenous immunoglobulin and cyclosporin.

Advances in Knowledge A computational bootstrapping of the clinicopathological picture of PV was conducted to provide a state-of-the-art view on the validity of following each treatment modality. Although all profiles are deficient in providing data for many items, corticosteroid therapy is the most investigated modality before and after receiving a treatment course.